Avi Orr-Urtreger

List of Publications by Year
in descending order

168 papers	8,309 citations	41344 49 h-index	56724 83 g-index
171 all docs	171 docs citations	171 times ranked	10069 citing authors

#	Article	IF	Citations
1	Developmental Localization of the Splicing Alternatives of Fibroblast Growth Factor Receptor-2 (FGFR2). Developmental Biology, 1993, 158, 475-486.	2.0	509
2	Mice Deficient in the Î±7 Neuronal Nicotinic Acetylcholine Receptor Lack Î±-Bungarotoxin Binding Sites and Hippocampal Fast Nicotinic Currents. Journal of Neuroscience, 1997, 17, 9165-9171.	3.6	478
3	Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology, 2015, 84, 880-887.	1.1	277
4	Î±7 Nicotinic Receptor Subunits Are Not Necessary for Hippocampal-Dependent Learning or Sensorimotor Gating: A Behavioral Characterization of Acra7-Deficient Mice. Learning and Memory, 1998, 5, 302-316.	1.3	271
5	Multiorgan Autonomic Dysfunction in Mice Lacking the Î²2 and the Î²4 Subunits of Neuronal Nicotinic Acetylcholine Receptors. Journal of Neuroscience, 1999, 19, 9298-9305.	3.6	263
6	Activation of the Cholinergic Anti-Inflammatory System by Nicotine Attenuates Neuroinflammation via Suppression of Th1 and Th17 Responses. Journal of Immunology, 2009, 183, 6681-6688.	0.8	244
7	The Nicotinic Acetylcholine Receptor Subunit Î±5 Mediates Short-Term Effects of Nicotine in Vivo. Molecular Pharmacology, 2003, 63, 1059-1066.	2.3	182
8	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nature Medicine, 2018, 24, 1867-1876.	30.7	179
9	Decreased first trimester PAPPâ€A is a predictor of adverse pregnancy outcome. Prenatal Diagnosis, 2002, 22, 778-782.	2.3	167
10	The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology, 2013, 80, 1606-1610.	1.1	149
11	A Genome-Wide Scan of Ashkenazi Jewish Crohn's Disease Suggests Novel Susceptibility Loci. PLoS Genetics, 2012, 8, e1002559.	3.5	144
12	Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Annals of Neurology, 2011, 69, 193-197.	5.3	140
13	Central role of Î±7 nicotinic receptor in differentiation of the stratified squamous epithelium. Journal of Cell Biology, 2002, 159, 325-336.	5.2	136
14	Arm swing as a potential new prodromal marker of Parkinson's disease. Movement Disorders, 2016, 31, 1527-1534.	3.9	136
15	Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations. Movement Disorders, 2013, 28, 1966-1971.	3.9	131
16	Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology, 2015, 85, 89-95.	1.1	130
17	Mice Homozygous for the L250T Mutation in the Î±7 Nicotinic Acetylcholine Receptor Show Increased Neuronal Apoptosis and Die Within 1 Day of Birth. Journal of Neurochemistry, 2008, 74, 2154-2166.	3.9	118
18	GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder. Annals of Clinical and Translational Neurology, 2015, 2, 941-945.	3.7	117

#	Article	IF	Citations
19	A Novel Founder Mutation in the RNASEL Gene, 471delAAAG, Is Associated with Prostate Cancer in Ashkenazi Jews. American Journal of Human Genetics, 2002, 71, 981-984.	6.2	113
20	Progression in the LRRK2-Associated Parkinson Disease Population. JAMA Neurology, 2018, 75, 312.	9.0	109
21	Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Research, 2002, 62, 6803-7.	0.9	106
22	Central Role of Fibroblast Î±3 Nicotinic Acetylcholine Receptor in Mediating Cutaneous Effects of Nicotine. Laboratory Investigation, 2003, 83, 207-225.	3.7	95
23	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurology, The, 2020, 19, 71-80.	10.2	94
24	Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism and Related Disorders, 2018, 55, 45-49.	2.2	90
25	Fall risk and gait in Parkinson's disease: The role of the LRRK2 G2019S mutation. Movement Disorders, 2013, 28, 1683-1690.	3.9	82
26	Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3770-3774.	7.1	81
27	Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer. Gastroenterology, 1999, 116, 54-57.	1.3	78
28	A â€œdoseâ€•effect of mutations in the GBA gene on Parkinson's disease phenotype. Parkinsonism and Related Disorders, 2017, 36, 47-51.	2.2	78
29	Mice lacking neuronal nicotinic acetylcholine receptor Î²4-subunit and mice lacking both Î±5- and Î²4-subunits are highly resistant to nicotine-induced seizures. Physiological Genomics, 2004, 17, 221-229.	2.3	76
30	Higher Frequency of Certain Cancers inLRRK2G2019S Mutation Carriers With Parkinson Disease. JAMA Neurology, 2015, 72, 58.	9.0	76
31	Rett Syndrome: Clinical Manifestations in Males With MECP2 Mutations. Journal of Child Neurology, 2002, 17, 20-24.	1.4	75
32	Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. Neurology, 2012, 79, 1027-1032.	1.1	75
33	Autonomic function in mice lacking Î±5 neuronal nicotinic acetylcholine receptor subunit. Journal of Physiology, 2002, 542, 347-354.	2.9	73
34	Synergistic control of keratinocyte adhesion through muscarinic and nicotinic acetylcholine receptor subtypes. Experimental Cell Research, 2004, 294, 534-549.	2.6	73
35	The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. Progress in Neurobiology, 2002, 68, 341-360.	5.7	72
36	Carrier Screening for Gaucher Disease. JAMA - Journal of the American Medical Association, 2007, 298, 1281.	7.4	68

#	Article	IF	Citations
37	First Trimester Maternal Serum Free Human Chorionic Gonadotropin as a Predictor of Adverse Pregnancy Outcome. Fetal Diagnosis and Therapy, 2002, 17, 352-356.	1.4	67
38	Altered baroreflex responses in Î±7 deficient mice. Behavioural Brain Research, 2000, 113, 3-10.	2.2	66
39	Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers. Neurology, 2015, 84, 399-406.	1.1	66
40	Variable Clinical Presentation of an MUC1 Mutation Causing Medullary Cystic Kidney Disease Type 1. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 527-535.	4.5	65
41	Genetic Testing in Israel: An Overview. Annual Review of Genomics and Human Genetics, 2009, 10, 175-192.	6.2	64
42	Maternal serum HCG is higher in the presence of a female fetus as early as week 3 post-fertilization. Human Reproduction, 2002, 17, 485-489.	0.9	58
43	Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 106-110.	2.2	58
44	Increased severity of experimental colitis in alpha5 nicotinic acetylcholine receptor subunit-deficient mice. NeuroReport, 2005, 16, 1123-1127.	1.2	57
45	FGFR1 overâ€expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5â€² CpG Island and abnormal expression of the AKT1, NOG, and BMP4 genes. Genes Chromosomes and Cancer, 2007, 46, 1028-1038.	2.8	57
46	The LRRK2 G2019S mutation as the cause of Parkinsonâ€™s disease in Ashkenazi Jews. Journal of Neural Transmission, 2009, 116, 1473-1482.	2.8	54
47	Novel Genes Implicated in Embryonal, Alveolar, and Pleomorphic Rhabdomyosarcoma: A Cytogenetic and Molecular Analysis of Primary Tumors. Neoplasia, 2006, 8, 332-343.	5.3	53
48	Biochemical and functional properties of distinct nicotinic acetylcholine receptors in the superior cervical ganglion of mice with targeted deletions of nAChR subunit genes. European Journal of Neuroscience, 2010, 31, 978-993.	2.6	52
49	Association of Sequence Alterations in the Putative Promoter of <emph type="ital">RAB7L1</emph> With a Reduced Parkinson Disease Risk. Archives of Neurology, 2012, 69, 105.	4.5	52
50	Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene. Movement Disorders, 2015, 30, 981-986.	3.9	52
51	Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. Human Molecular Genetics, 2014, 23, 4693-4702.	2.9	49
52	The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1Î± is associated with increased risk for prostate cancer. Prostate, 2007, 67, 8-13.	2.3	48
53	Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans. Human Molecular Genetics, 2010, 19, 1998-2004.	2.9	48
54	High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews. JAMA Neurology, 2016, 73, 1448.	9.0	48

#	Article	IF	Citations
55	High Frequency of a Common Bloom Syndrome Ashkenazi Mutation Among Jews of Polish Origin. Genetic Testing and Molecular Biomarkers, 1998, 2, 293-296.	1.7	45
56	Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers. Cortex, 2013, 49, 2501-2511.	2.4	42
57	Mechanism, Prevalence, and More Severe Neuropathy Phenotype of the Charcot-Marie-Tooth Type 1A Triplication. American Journal of Human Genetics, 2014, 94, 462-469.	6.2	42
58	Functional role of Î±7 nicotinic receptor in physiological control of cutaneous homeostasis. Life Sciences, 2003, 72, 2063-2067.	4.3	41
59	Effect of fetal gender on first trimester markers and on Down syndrome screening. Prenatal Diagnosis, 2001, 21, 1027-1030.	2.3	40
60	Screening for Familial Dysautonomia in Israel: Evidence for Higher Carrier Rate among Polish Ashkenazi Jews. Genetic Testing and Molecular Biomarkers, 2003, 7, 139-142.	1.7	39
61	Deficiency of Nicotinic Acetylcholine Receptor Î²4 Subunit Causes Autonomic Cardiac and Intestinal Dysfunction. Molecular Pharmacology, 2003, 63, 574-580.	2.3	39
62	OPTN 691_692insAG is a founder mutation causing recessive ALS and increased risk in heterozygotes. Neurology, 2016, 86, 446-453.	1.1	37
63	Cloning and mapping of the mouse Î±7-neuronal nicotinic acetylcholine receptor. Genomics, 1995, 26, 399-402.	2.9	36
64	Initial experience of videocapsule endoscopy for diagnosing small-bowel tumors in patients with GI polyposis syndromes. Gastrointestinal Endoscopy, 2005, 62, 448-452.	1.0	36
65	Large-scale population screening for spinal muscular atrophy: Clinical implications. Genetics in Medicine, 2011, 13, 110-114.	2.4	36
66	Molecular analysis of the APC gene in 71 Israeli families: 17 novel mutations. Human Mutation, 2002, 19, 664-664.	2.5	35
67	Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease. Movement Disorders, 2020, 35, 959-968.	3.9	34
68	Clinical and screening implications of the I1307K adenomatous polyposis coli gene variant in Israeli Ashkenazi Jews with familial colorectal neoplasia. Cancer, 2002, 94, 2561-2568.	4.1	33
69	Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. Brain, 2012, 135, 3687-3698.	7.6	33
70	The emerging role of SMPD1 mutations in Parkinson's disease: Implications for future studies. Parkinsonism and Related Disorders, 2015, 21, 1294-1295.	2.2	33
71	The 8765delAG Mutation in BRCA2 Is Common among Jews of Yemenite Extraction. American Journal of Human Genetics, 1998, 63, 272-274.	6.2	32
72	MECP2 Mutations in Israel: Implications for molecular analysis, genetic counseling, and prenatal diagnosis in Rett syndrome. Human Mutation, 2002, 20, 323-324.	2.5	31

#	Article	IF	Citations
73	Lower core body temperature and attenuated nicotine-induced hypothermic response in mice lacking the Î²4 neuronal nicotinic acetylcholine receptor subunit. Brain Research Bulletin, 2005, 66, 30-36.	3.0	31
74	LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis. Parkinsonism and Related Disorders, 2015, 21, 778-782.	2.2	30
75	Selective deletion of the Î±5 subunit differentially affects somatic-dendriticversusaxonally targeted nicotinic ACh receptors in mouse. Journal of Physiology, 2005, 563, 119-137.	2.9	29
76	Functional Analysis of the Aurora Kinase A Ile31 Allelic Variant in Human Prostate. Neoplasia, 2007, 9, 707-IN25.	5.3	29
77	The Risk of Fragile X Premutation Expansion Is Lower in Carriers Detected by General Prenatal Screening Than in Carriers from Known Fragile X Families. Genetic Testing and Molecular Biomarkers, 2000, 4, 289-292.	1.7	28
78	Advances in the genetics of Parkinson's disease. Acta Pharmacologica Sinica, 2008, 29, 21-34.	6.1	27
79	Being â€˜at-riskâ€™ for developing cancer: cognitive representations and psychological outcomes. Journal of Behavioral Medicine, 2009, 32, 197-208.	2.1	27
80	A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease. Movement Disorders, 2020, 35, 1249-1253.	3.9	27
81	Multiplex Nested PCR for Preimplantation Genetic Diagnosis of Spinal Muscular Atrophy. Fetal Diagnosis and Therapy, 2004, 19, 199-206.	1.4	26
82	Array-Based Comparative Genome Hybridization in Clinical Genetics. Pediatric Research, 2006, 60, 353-358.	2.3	26
83	Cytogenetic analysis of three variants of clival chordoma. Cancer Genetics and Cytogenetics, 2004, 154, 124-130.	1.0	25
84	Mutation screening and association study of the candidate prostate cancer susceptibility genesMSR1,PTEN, andKLF6. Prostate, 2006, 66, 1052-1060.	2.3	25
85	The Age at Motor Symptoms Onset in LRRK2-Associated Parkinson's Disease is Affected by a Variation in the MAPT Locus: A Possible Interaction. Journal of Molecular Neuroscience, 2012, 46, 541-544.	2.3	25
86	Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?. Molecular Genetics and Metabolism, 2019, 128, 470-475.	1.1	25
87	Analysis of theHoxd-3Gene: Structure and Localization of Its Sense and Natural Antisense Transcripts. DNA and Cell Biology, 1995, 14, 295-304.	1.9	24
88	RNASELMutation Screening and Association Study in Ashkenazi and Non-Ashkenazi Prostate Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 474-479.	2.5	24
89	Ashkenazi Parkinsonâ€™s disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. Neurogenetics, 2009, 10, 355-358.	1.4	23
90	Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease. Molecular Neurodegeneration, 2011, 6, 66.	10.8	23

#	Article	IF	Citations
91	Interest in Genetic Testing in Ashkenazi Jewish Parkinson's Disease Patients and Their Unaffected Relatives. Journal of Genetic Counseling, 2015, 24, 238-246.	1.6	23
92	Cerebral Imaging Markers of GBA and LRRK2 Related Parkinsonâ€™s Disease and Their First-Degree Unaffected Relatives. Brain Topography, 2018, 31, 1029-1036.	1.8	23
93	Increased sensitivity to nicotine-induced seizures in mice heterozygous for the L250T mutation in the Î±7 nicotinic acetylcholine receptor. NeuroReport, 2002, 13, 191-196.	1.2	22
94	Subunit composition of Î±5â€containing nicotinic receptors in the rodent habenula. Journal of Neurochemistry, 2012, 121, 551-560.	3.9	22
95	A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers. Brain Structure and Function, 2017, 222, 1207-1218.	2.3	22
96	HIF1AC1772T polymorphism leads to HIF-1Î± mRNA overexpression in prostate cancer patients. Cancer Biology and Therapy, 2012, 13, 720-726.	3.4	21
97	Sperm Epidermal Growth Factor Receptor (EGFR) Mediates Î±7 Acetylcholine Receptor (AChR) Activation to Promote Fertilization. Journal of Biological Chemistry, 2012, 287, 22328-22340.	3.4	21
98	Two novel mutations identified in familial cases with Donohue syndrome. Molecular Genetics & Genomic Medicine, 2014, 2, 64-72.	1.2	21
99	A Personalized Approach to Parkinsonâ€™s Disease Patients Based on Founder Mutation Analysis. Frontiers in Neurology, 2016, 7, 71.	2.4	21
100	Down-regulation of B cell-related genes in peripheral blood leukocytes of Parkinson's disease patients with and without GBA mutations. Molecular Genetics and Metabolism, 2016, 117, 179-185.	1.1	21
101	A voxelâ€based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's diseaseâ€related G2019S LRRK2 mutation carriers. Movement Disorders, 2014, 29, 823-827.	3.9	20
102	Genetic markers of Restless Legs Syndrome in Parkinson disease. Parkinsonism and Related Disorders, 2015, 21, 582-585.	2.2	20
103	Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation. Brain Imaging and Behavior, 2019, 13, 1009-1020.	2.1	20
104	Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinsonâ€™s disease. Scientific Reports, 2020, 10, 9329.	3.3	19
105	Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity. Movement Disorders, 2022, 37, 190-195.	3.9	19
106	First trimester PAPP-A in the detection of non-Down syndrome aneuploidy. Prenatal Diagnosis, 2001, 21, 547-549.	2.3	16
107	Intact working memory in nonâ€manifesting <scp>LRRK</scp>2 carriers â€“ an <scp>fMRI</scp> study. European Journal of Neuroscience, 2016, 43, 106-112.	2.6	16
108	Network abnormalities among nonâ€manifesting Parkinson disease related LRRK2 mutation carriers. Human Brain Mapping, 2019, 40, 2546-2555.	3.6	16

#	Article	IF	Citations
109	Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. Journal of Parkinson's Disease, 2021, 11, 1285-1296.	2.8	16
110	The clinical application of spectral karyotyping (SKY?) in the analysis of prenatally diagnosed extra structurally abnormal chromosomes (ESACs). Prenatal Diagnosis, 2003, 23, 74-79.	2.3	15
111	Cytogenetic Analysis of Sinonasal Carcinomas. Otolaryngology - Head and Neck Surgery, 2006, 134, 654-660.	1.9	15
112	Interspecies comparison of prostate cancer geneâ€expression profiles reveals genes associated with aggressive tumors. Prostate, 2009, 69, 1034-1044.	2.3	15
113	Fighting the risk of developing Parkinson's disease; clinical counseling for first degree relatives of patients with Parkinson's disease. Journal of the Neurological Sciences, 2011, 310, 17-20.	0.6	15
114	Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease. Neurogenetics, 2011, 12, 325-332.	1.4	15
115	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). Parkinsonism and Related Disorders, 2019, 62, 201-209.	2.2	15
116	Familial adenomatous polyposis at the Tel Aviv Medical Center: demographic and clinical features. Familial Cancer, 2001, 1, 75-82.	1.9	14
117	A Comparison between Maternal Serum Free Î²-Human Chorionic Gonadotrophin and Pregnancy-Associated Plasma Protein A Levels in First-Trimester Twin and Singleton Pregnancies. Fetal Diagnosis and Therapy, 2004, 19, 174-177.	1.4	14
118	Singleâ€channel properties of Î±3Î²4, Î±3Î²4Î±5 and Î±3Î²4Î²2 nicotinic acetylcholine receptors in mice lacking specific nicotinic acetylcholine receptor subunits. Journal of Physiology, 2013, 591, 3271-3288.	2.9	14
119	Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes. Movement Disorders, 2018, 33, 1656-1660.	3.9	14
120	Fetal muscle biopsy as a diagnostic tool in Duchenne muscular dystrophy. , 1999, 19, 921-926.		13
121	Normal apoptosis levels in mice expressing one Î±7 nicotinic receptor null and one L250T mutant allele. NeuroReport, 2001, 12, 1643-1648.	1.2	13
122	Combined cytogenetic and array-based comparative genomic hybridization analyses of Wilms tumors. Cancer Genetics and Cytogenetics, 2003, 141, 120-127.	1.0	13
123	Two novel translocations, t(2;4)(q35;q31) and t(X;12)(q22;q24), as the only karyotypic abnormalities in a malignant peripheral nerve sheath tumor of the skull base. Cancer Genetics and Cytogenetics, 2003, 145, 139-143.	1.0	13
124	SEPT14 Is Associated with a Reduced Risk for Parkinsonâ€™s Disease and Expressed in Human Brain. Journal of Molecular Neuroscience, 2016, 59, 343-350.	2.3	13
125	A founder mutation in ADAMTSL4 causes early-onset bilateral ectopia lentis among Jews of Bukharian origin. Molecular Genetics and Metabolism, 2016, 117, 38-41.	1.1	13
126	Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease. Frontiers in Neurology, 2019, 10, 531.	2.4	13

#	Article	IF	Citations
127	Differential brain transcriptome of Î²4 nAChR subunit-deficient mice: is it the effect of the null mutation or the background strain?. Physiological Genomics, 2007, 28, 213-222.	2.3	12
128	TnfÎ±, Cox2 and AdipoQ adipokine gene expression levels are modulated in murine adipose tissues by both nicotine and nACh receptors containing the Î²2 subunit. Molecular Genetics and Metabolism, 2012, 107, 561-570.	1.1	12
129	Ethnic effect on FMR1 carrier rate and AGG repeat interruptions among Ashkenazi women. Genetics in Medicine, 2014, 16, 940-944.	2.4	12
130	The Effect of GBA Mutations and APOE Polymorphisms on Dementia with Lewy Bodies in Ashkenazi Jews. Journal of Alzheimer's Disease, 2021, 80, 1221-1229.	2.6	12
131	High frequency of C9orf72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis patients from two founder populations sharing the same risk haplotype. Neurobiology of Aging, 2018, 64, 160.e1-160.e7.	3.1	11
132	Nicotinic acetylcholine receptor Î±5 subunits modulate oxotremorine-induced salivation and tremor. Journal of the Neurological Sciences, 2004, 222, 87-91.	0.6	10
133	Expression changes in mouse brains following nicotine-induced seizures: the modulation of transcription factor networks. Physiological Genomics, 2007, 30, 242-252.	2.3	10
134	Î±4Î²2 nicotinic acetylcholine receptors in the early postnatal mouse superior cervical ganglion. Developmental Neurobiology, 2011, 71, 390-399.	3.0	10
135	CHRNB3 c.-57A>G functional promoter change affects Parkinson's disease and smoking. Neurobiology of Aging, 2014, 35, 2179.e1-2179.e6.	3.1	10
136	Rare homozygosity in amyotrophic lateral sclerosis suggests the contribution of recessive variants to disease genetics. Journal of the Neurological Sciences, 2019, 402, 62-68.	0.6	10
137	False-positive results using a Gaucher diagnostic kit â€“ RecTL and N370S. Molecular Genetics and Metabolism, 2010, 100, 100-102.	1.1	9
138	Constitutional mosaicism for a chromosome 9 inversion resulting in recombinant aneusomy in an offspring. , 1997, 69, 360-364.		8
139	Hidden function of neuronal nicotinic acetylcholine receptor Î²2 subunits in ganglionic transmission: comparison to Î±5 and Î²4 subunits. Journal of the Neurological Sciences, 2005, 228, 167-177.	0.6	8
140	Cytogenetic analysis of 101 skull base tumors. Head and Neck, 2008, 30, 567-581.	2.0	8
141	Role of Î±5-containing nicotinic receptors in neuropathic pain and response to nicotine. Neuropharmacology, 2015, 95, 37-49.	4.1	8
142	The role of the nAChR subunits Î± 5, Î² 2, and Î² 4 on synaptic transmission in the mouse superior cervical ganglion. Physiological Reports, 2019, 7, e14023.	1.7	8
143	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. Genetics in Medicine, 2014, 16, 644-645.	2.4	7
144	Novel mutations in theemerin gene in Israeli families. Human Mutation, 2001, 17, 522-522.	2.5	6

#	Article	IF	Citations
145	Frequencies of C282Y and H63D alleles in the HFE gene among various Jewish ethnic groups in Israel: A change of concept required. Genetics in Medicine, 2010, 12, 122-125.	2.4	6
146	Predictive value of TP53 fluorescencein situhybridization in cytogenetic subgroups of acute myeloid leukemia. Leukemia and Lymphoma, 2011, 52, 642-647.	1.3	6
147	The effects of aging vs. Î±7 nAChR subunit deficiency on the mouse brain transcriptome: aging beats the deficiency. Age, 2011, 33, 1-13.	3.0	6
148	Segregation of a paternal insertional translocation results in partial 4q monosomy or 4q trisomy in two siblings. , 1996, 61, 10-15.		5
149	New Genetic Principles. Clinical Obstetrics and Gynecology, 2002, 45, 593-604.	1.1	5
150	An Alternative SplicedRNASELVariant in Peripheral Blood Leukocytes. Journal of Interferon and Cytokine Research, 2006, 26, 820-826.	1.2	5
151	Dynamic modification strategy of the Israeli carrier screening protocol: inclusion of the Oriental Jewish Group to the cystic fibrosis panel. Genetics in Medicine, 2009, 11, 101-103.	2.4	5
152	Undetected sex chromosome aneuploidy by chromosomal microarray. Prenatal Diagnosis, 2012, 32, 1117-1118.	2.3	5
153	Efficient estimation of nonparametric genetic risk function with censored data. Biometrika, 2015, 102, 515-532.	2.4	5
154	Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers. Npj Parkinson's Disease, 2022, 8, 20.	5.3	5
155	A founder mutation causing a severe methylenetetrahydrofolate reductase (MTHFR) deficiency in Bukharian Jews. Molecular Genetics and Metabolism, 2012, 107, 608-610.	1.1	4
156	PARK16 locus: Differential effects of the non-coding rs823114 on Parkinsonâ€™s disease risk, RNA expression, and DNA methylation. Journal of Genetics and Genomics, 2021, 48, 341-345.	3.9	4
157	Biochemical markers for severity and risk in GBA and LRRK2 Parkinsonâ€™s disease. Journal of Neurology, 2021, 268, 1517-1525.	3.6	4
158	Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity. Movement Disorders, 2022, 37, 651-652.	3.9	4
159	Two Ethnic Clusters with Huntington Disease in Israel: The Case of Mountain Jews and Karaites. Neurodegenerative Diseases, 2017, 17, 281-285.	1.4	3
160	Estimation of genetic risk function with covariates in the presence of missing genotypes. Statistics in Medicine, 2017, 36, 3533-3546.	1.6	3
161	Distinguishing Dementia With Lewy Bodies From Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2019, 33, 279-281.	1.3	2
162	The GBA-370Rec Parkinson's disease risk haplotype harbors a potentially pathogenic variant in the mitochondrial gene SLC25A44. Molecular Genetics and Metabolism, 2021, 133, 109-112.	1.1	2

#	Article	IF	Citations
163	C9orf72-G4C2 Intermediate Repeats and Parkinsonâ€™s Disease; A Data-Driven Hypothesis. Genes, 2021, 12, 1210.	2.4	2
164	Variable PARK2 Mutations Cause Early-Onset Parkinsonâ€™s Disease in a Small Restricted Population. Journal of Molecular Neuroscience, 2017, 63, 216-222.	2.3	1
165	R869C mutation in molecular motor KIF17 gene is involved in dementia with Lewy bodies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12143.	2.4	1
166	The Predictive Value of TP53 FISH Analysis for Treatment Response and Survival in Cytogenetic Subgroups of AML Patients.. Blood, 2009, 114, 2617-2617.	1.4	1
167	Clinical Observation: Effect of a Second Transpositioned Variant in a Family with Autosomal Dominant Ryanodine Receptor-1â€“Related Disease. Journal of Pediatric Genetics, 2020, 09, 121-124.	0.7	0
168	A novel mutation in TARDBP segregates with amyotrophic lateral sclerosis in a large family with early onset and fast progression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 280-285.	1.7	0